Investors & News

Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$61.37
Change (%) Stock is Up 1.94 (3.26%)
Volume214,979
Data as of 02/23/18 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $61.37 with a 52 week high of $63.00 and a 52 week low of $21.95.
Recent NewsMore >>
21/Feb/2018
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
20/Feb/2018
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
08/Feb/2018
Ascendis Pharma A/S Announces Participation in Leerink Partners 7th Annual Global Healthcare Conference
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma
E-mail: ir@ascendispharma.com

Data provided by Nasdaq. Minimum 15 minutes delayed.